Manufacturing jobs in the United States declined in 2025

I would say the Trump tariffs are not helping. I mean, mostly because there’s no larger coherent plan attached to them. Like they’re very chaotic in terms of like what country faces what raid and maybe that changes and it differs across industry. And even the rationale, like sometimes the tariffs are invoked as we’re trying to bring back manufacturing jobs. Sometimes they’re somehow related to things like fentanyl, and what they’re doing in the meantime is they’re making imports or inputs into *** lot of manufacturing goods. And so when they get more expensive, all of *** sudden the output of manufacturing. Firms gets very expensive and not competitive in global markets and other countries retaliate and we’ve seen *** really big reduction in manufacturing exports as *** share of the total economy so I think all in all um there’s just no plan here and the tariffs have definitely done more damage than help.

Get the Facts: Are Trump’s tariffs bringing back manufacturing jobs? Here’s the data

Updated: 4:40 PM CST Feb 11, 2026

Editorial Standards ⓘ

When President Donald Trump announced “reciprocal” tariffs last April, he promised it would help revitalize America’s manufacturing industry. Since that announcement, employment in the manufacturing industry has been in decline, according to an analysis by the Get the Facts Data Team using data from the Bureau of Labor Statistics.The loss of manufacturing jobs coincides with the softening in the labor market, said Josh Bivens, chief economist at the Economic Policy Institute, a Washington, D.C.-based nonpartisan think tank. There were about 12.2 million manufacturing employees in the sector when former President Joe Biden began his term. By the end of December 2024, near the end of his administration, the U.S. had about 12.7 million manufacturing employees.A year later, that number dropped by 108,000, according to the latest BLS jobs report. The industry has seen job losses each month since January 2025, but added 5,000 last month. Manufacturing is a major sector of the U.S. economy and supports other industries. But over the past 25 years, it’s been battered by globalization and policy mistakes that have put pressure on the industry, said Bivens. During the 2008 financial crisis, the manufacturing sector had steep job losses. Job growth began stabilizing in the late 2010s and held steady through the end of 2019 under President Trump’s first term. However, employment declined again following COVID-19. Since 2000, the sector has lost approximately five million jobs.Another challenge the industry is facing right now: Trump’s tariffs. According to Bivens, tariffs are currently doing more damage than helping the sector. Tariffs make imports expensive, which also makes manufacturing outputs expensive, making it harder for firms to compete in global markets. Countries can also retaliate and add their own tariffs on their goods.But Bivens points out tariffs can be beneficial in some cases; however, what he’s seeing from this administration doesn’t show evidence of a larger plan, and tariff decisions tend to be erratic. Some U.S. states, particularly in the Midwest, have a higher share of manufacturing jobs and rely on the sector. But more than half of U.S. states had a decline in manufacturing employment over the past year. Alaska had the steepest percentage drop at 6%, a loss of 800 employees. Montana and Oregon followed, with declines of roughly 5% and 3%.California, Texas and Ohio have the highest total number of manufacturing employees, but only Ohio reported job growth, gaining 8,500 employees over the year. California lost 32,600 employees, a 2.3% loss. “Manufacturing is still a place where you have a lot of workers without a college degree,” said Bivens. “When they lose a manufacturing job, they’re a little less likely to find a job with equivalent pay and equivalent benefits.” PHNjcmlwdCB0eXBlPSJ0ZXh0L2phdmFzY3JpcHQiPiFmdW5jdGlvbigpeyJ1c2Ugc3RyaWN0Ijt3aW5kb3cuYWRkRXZlbnRMaXN0ZW5lcigibWVzc2FnZSIsKGZ1bmN0aW9uKGUpe2lmKHZvaWQgMCE9PWUuZGF0YVsiZGF0YXdyYXBwZXItaGVpZ2h0Il0pe3ZhciB0PWRvY3VtZW50LnF1ZXJ5U2VsZWN0b3JBbGwoImlmcmFtZSIpO2Zvcih2YXIgYSBpbiBlLmRhdGFbImRhdGF3cmFwcGVyLWhlaWdodCJdKWZvcih2YXIgcj0wO3I8dC5sZW5ndGg7cisrKXtpZih0W3JdLmNvbnRlbnRXaW5kb3c9PT1lLnNvdXJjZSl0W3JdLnN0eWxlLmhlaWdodD1lLmRhdGFbImRhdGF3cmFwcGVyLWhlaWdodCJdW2FdKyJweCJ9fX0pKX0oKTs8L3NjcmlwdD4=

WASHINGTON —

When President Donald Trump announced “reciprocal” tariffs last April, he promised it would help revitalize America’s manufacturing industry.

Since that announcement, employment in the manufacturing industry has been in decline, according to an analysis by the Get the Facts Data Team using data from the Bureau of Labor Statistics.

The loss of manufacturing jobs coincides with the softening in the labor market, said Josh Bivens, chief economist at the Economic Policy Institute, a Washington, D.C.-based nonpartisan think tank.

There were about 12.2 million manufacturing employees in the sector when former President Joe Biden began his term. By the end of December 2024, near the end of his administration, the U.S. had about 12.7 million manufacturing employees.

A year later, that number dropped by 108,000, according to the latest BLS jobs report. The industry has seen job losses each month since January 2025, but added 5,000 last month.

Manufacturing is a major sector of the U.S. economy and supports other industries. But over the past 25 years, it’s been battered by globalization and policy mistakes that have put pressure on the industry, said Bivens.

During the 2008 financial crisis, the manufacturing sector had steep job losses. Job growth began stabilizing in the late 2010s and held steady through the end of 2019 under President Trump’s first term. However, employment declined again following COVID-19. Since 2000, the sector has lost approximately five million jobs.

Another challenge the industry is facing right now: Trump’s tariffs. According to Bivens, tariffs are currently doing more damage than helping the sector. Tariffs make imports expensive, which also makes manufacturing outputs expensive, making it harder for firms to compete in global markets. Countries can also retaliate and add their own tariffs on their goods.

But Bivens points out tariffs can be beneficial in some cases; however, what he’s seeing from this administration doesn’t show evidence of a larger plan, and tariff decisions tend to be erratic.

Some U.S. states, particularly in the Midwest, have a higher share of manufacturing jobs and rely on the sector.

But more than half of U.S. states had a decline in manufacturing employment over the past year. Alaska had the steepest percentage drop at 6%, a loss of 800 employees. Montana and Oregon followed, with declines of roughly 5% and 3%.

California, Texas and Ohio have the highest total number of manufacturing employees, but only Ohio reported job growth, gaining 8,500 employees over the year. California lost 32,600 employees, a 2.3% loss.

“Manufacturing is still a place where you have a lot of workers without a college degree,” said Bivens. “When they lose a manufacturing job, they’re a little less likely to find a job with equivalent pay and equivalent benefits.”

Source link

Manufacturing Construction Spending Declines Despite Trump’s “41% Up” Claim

Spending to build and expand U.S. manufacturing facilities has fallen since President Donald Trump returned to office, according to U.S. Census Bureau figures — a trend that conflicts with the president’s repeated assertion that factory construction is soaring.

Trump has frequently cited a “41% increase” in factory investment, portraying it as proof that his trade and economic policies are fueling a manufacturing boom.

“Investment in American factories is up 41%. That’s a record. Nobody goes 41% up. You go 2% up, 1% up. You go down by 3%. If Kamala [Harris] got elected, the 41% up would be 41% down,” Trump said at a White House press conference on Jan. 20.

Courtesy: Photo by Schiba on Unsplash

He repeated the claim the next day at the World Economic Forum in Davos:

“Factory construction is up by 41%, and that number is really going to skyrocket right now, because that’s during a process that they’re putting in to get their approvals and we’ve given very, very quick, fast approvals.”

FactCheck.org reviewed the underlying data and found a different picture: manufacturing construction spending peaked in 2024 during the Biden administration and has edged downward since.

What the Census Data Actually Show

Under President Joe Biden, manufacturing construction experienced an unprecedented surge. Annual average spending rose more than 200%, climbing from $75.5 billion in 2021 to $235.6 billion in 2024, driven largely by the bipartisan CHIPS and Science Act and post-pandemic reshoring.

Economist Anirban Basu of the Associated Builders and Contractors explained the early momentum:

“Supply chain disruptions at the start of the COVID-19 pandemic convinced many producers to reshore capacity, while a sudden and sharp increase in construction materials prices—which rose more than 40% during the early years of the pandemic—also boosted nominal construction spending.”

However, quarterly Census data indicate that from late 2024 through the third quarter of 2025 — Trump’s first months back in office — spending declined 6.7%. Monthly figures show a 7.3% drop from January to October 2025.

The American Institute of Architects expects further cooling:

“Manufacturing construction spending has seen phenomenal growth… However, growth paused last year as spending in this category fell about 5% and is projected to decline another 4% this year and 1% in 2027.”

Where the “41%” Figure Came From

After multiple inquiries, the White House told FactCheck.org it compared January–August 2025 spending with the average of 2021–2024, producing roughly a 40% increase. But the methodology ignores that the entire surge occurred under Biden and that spending has since softened.

Basu attributed the recent slowdown partly to Trump’s tariff policies:

“With CHIPS Act-enabled megaprojects winding down and the stiff headwind of trade policy, manufacturing construction spending has fallen by nearly 10% over the past 12 months.”

He added that 2025 activity remains elevated “largely due to the surge in megaproject activity induced by the CHIPS Act.”

Tariffs have also pushed up costs:

“[I]t should be noted that spending in the fabricated metal manufacturing subsegment is up 19% over the past year. Some of the increase can be contributed to tariffs and the resulting increase in demand for domestic production.”

Jobs Haven’t Followed the Spending

Despite billions poured into new facilities, manufacturing employment has continued to slip. The Bureau of Labor Statistics shows the economy lost 63,000 manufacturing jobs in Trump’s first 11 months, following a loss of 98,000 in the prior 11 months.

Industry observers say job growth may come later. A December 2024 article in Manufacturing Today noted:

“Unlike traditional industrial projects, today’s semiconductor and clean energy facilities require longer timelines. Factories of this scale can take two to three years to complete… This extended timeline means the full benefits will not be realized for several more years.”

Courtesy: Photo by Pixabay on Pexels

Basu agreed but warned tariffs could blunt those gains:

“The massive facilities incentivized by the CHIPS Act will employ thousands of people. That said… recent trade policy and the effects on manufacturing input prices have put downward pressure on the industry’s employment.”

Mixed Views on Tariffs

Some analysts remain optimistic. Morgan Stanley’s Chris Snyder called tariffs “a positive catalyst” for relocating production:

“What we’re seeing is the cost of imports have gone higher with tariffs, and now it’s more economically advisable for these companies to make the product in the United States.”

Others disagree. The Wall Street Journal reported that tariffs “haven’t worked, so far,” increasing costs and creating uncertainty that executives view as “a lost year for investment.”

Bottom Line

While factory construction remains historically high, the recent trajectory under Trump is downward, not upward. The oft-repeated 41% claim relies on a comparison that credits Biden-era spending to the current administration.

As FactCheck.org concluded, “factory construction so far has declined under Trump and his claim that it has increased 41% depends on a spending surge that occurred under Biden.”

Originally reported by Eugene Kiely in Fact Check.

Source link

Japanese manufacturer selects San Antonio for first U.S. facility, headquarters

Sanko Texas Corporation will break ground on its first U.S. plant in San Antonio, highlighting the city’s economic growth and strengthening U.S.-Japan trade ties.

SAN ANTONIO — Sanko Texas Corporation, a Japanese manufacturer, will break ground Wednesday on its first U.S. manufacturing facility, marking the company’s initial expansion into the United States and the establishment of its U.S. headquarters in San Antonio.

The groundbreaking ceremony is scheduled for 11:15 a.m. Wednesday, Feb. 11, 2026, at the Sanko Texas Corporation site at 16586 Watson Road in southern Bexar County.

Local and regional officials said the investment reflects San Antonio’s strengths in workforce talent, infrastructure and business climate, which have helped attract global manufacturers. By choosing San Antonio, Sanko joins a rapidly growing advanced manufacturing sector in Texas that plays a significant role in regional economic growth.

The project also highlights economic ties between the region and Japan, while reflecting coordinated efforts by local and regional partners to attract international investment.

Expected to attend the ceremony are Bexar County Judge Peter Sakai; San Antonio Mayor Gina Ortiz Jones; Bexar County Commissioner Rebecca Clay-Flores of Precinct 1; San Antonio City Councilwoman Phyllis Viagran of District 3; members of Sanko leadership and local business leaders.

Source link

Manufacturing plant headed to Upper Macungie – Lehigh Valley Press

Eli Lilly and Company and the Lehigh Valley are joining together to build a new state-of-the-art manufacturing facility that will be designed for the research and production of injectable weight loss medications.

On Jan. 30 at Curiosity Hall in the Da Vinci Science Center, Allentown, an assortment of community members, business and political stakeholders joined Eli Lilly and Company Chair and Chief Executive Officer Dave Ricks and Pennsylvania Gov. Josh Shapiro to announce a major collaboration.

Ricks said it is expanding manufacturing sites in the United States and considered 800 applicants for this project before choosing the Lehigh Valley. He credits the tenacity of Shapiro as this project will come to fruition at a site in Upper Macungie.

“Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we’re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines. We’re creating high‑quality jobs and collaborating across the region – with suppliers, educators and workforce development partners – to make critical medicines in the U.S.,” Ricks said. “That’s our commitment – to patients, to our new Pennsylvania home and to our country.”

The property in Upper Macungie Township, owned by the Jaindl Corporation (under contract to buy), will be the “single largest investment in economic development since the days of Bethlehem Steel,” said Lehigh Valley Economic Development Corporation president and CEO Don Cunningham. Manufacturing in Pennsylvania is 4 percent higher than the national average and is the largest industry within the state. Lilly proposes to invest $3.5 billion in this specific project. This will boost the Lehigh Valley economy on many levels.

For every dollar Lilly invests, it estimates up to $4 in additional local economic activity.

Ricks said Lilly is committed to the community and an interactive workforce development by including existing businesses and educational opportunities in its program. Lilly will connect with local nonprofits and encourage volunteerism.

Lehigh County Executive Josh Siegel pointed out, “Things are still made in the valley and we should be proud of that. This is more than creating jobs and buildings; it is creating futures and careers for our residents and their families.”

This project will employ 850 engineers, scientists, operations personnel and lab technicians.

Lehigh Valley Building and Construction Trades Council President Paul Anthony pointed out the many benefits of the shared commitment to building a safe, quality facility by skilled union tradesmen. “Government, businesses and labor, working together has made this project happen,” Anthony said.

This project will offer employment in the building trades, as well as apprenticeships leading to skilled union jobs. Construction is expected to begin this year and expects to create 2,000 construction jobs. The site will be operational in 2031.

Shapiro also pointed out the permitting reforms, the Pennsylvania Economic Development for a Growing Economy (PA EDGE), a collection of tax credit programs designed to attract new investments from businesses in critical manufacturing sectors, as well as The Pennsylvania Strategic Investments to Enhance Sites Program (PA SITES), established to provide grant and loan funding to eligible applicants, helped this project.

PA SITES invested an initial $500,000.

The PA SITES program encourages businesses to build or relocate within Pennsylvania. The funding for the program includes two components that support the development of competitive sites within the commonwealth, and expansion of existing sites. Funding is made available through planning grants, construction grants and loans

Ricks said this project is where “Curiosity meets Capability.” He reminded the audience of Lilly’s long history with pharmaceuticals starting post-Civil war. The emphasis was on defining ingredients and making safe, quality, accessible and affordable drugs for all Americans.”

The Lilly name will be seen throughout the valley.

“If it bares the red Lilly, you know it’s right,” Ricks said.

Gov. Josh Shapiro and Eli Lilly and Company CEO Dave Ricks place the Lilly pin/marker on the map of the Lehigh Valley, denoting where Lilly will make their mark.

PRESS PHOTOS BY JENN RAGOEli Lilly and Company and the Lehigh Valley are joining together to build a new state-of-the-art manufacturing facility where 850 new pharmaceutical jobs and 2,000 union construction jobs will be available in the Lehigh Valley with the proposed manufacturing plant in Upper Macungie Township.

Lehigh Valley Economic Development Corporation President and CEO Don Cunningham points out this was a bipartisan effort. Cunningham was instrumental in unifying all parties involved in this project.

“We still make things happen here [in the valley. This project shows government delivering,” Lehigh County Executive Josh Siegel tells the crowd.

Eli Lilly and Company Chair and Chief Executive Officer Dave Ricks tells the audience “800 municipalities and sites were considered for this project.” Upper Macungie Township was chosen for Lilly’s injectable manufacturing plant.

Source link

Fresenius Kabi and Phlow Corp. Enter First US End-to-End Manufacturing Collaboration

Fresenius Kabi and Phlow Corp. have announced a collaboration to onshore the manufacture of epinephrine injection, USP, including the production of APIs and finished doses.¹ This first-of-its-kind initiative represents a strategic response to the chronic shortages that have long impacted the availability of this essential medicine in the US. The arrangement utilizes a divided production model where Phlow Corp. produces the APIs at its advanced manufacturing campus in Virginia, while Fresenius Kabi manages the formulation and production of finished doses at its existing US facilities.

How Does This End-To-End Model Address Domestic Supply Chain Vulnerabilities?

The integration of API and finished dose manufacturing is a significant development because, while domestic production of the finished injection has existed, there has been no US-based source for the epinephrine API. To address this gap, a successful US-based validation campaign for the API was recently completed, and a Drug Master File has been filed with FDA.¹ This move aligns with a broader local-for-local strategy supported by over $1 billion in investments to modernize domestic manufacturing and logistics centers. Joel Rosenstack, president, US pharmaceuticals at Fresenius Kabi, stated in a press release,¹ “Fresenius is a committed partner in advancing America’s vision of a fully domestic, end-to-end, supply chain for essential medicines, closing a vital gap in national security.” By establishing a domestic source for both components, the collaboration aims to secure the supply of a drug indicated for critical applications, including the treatment of anaphylaxis and increasing mean arterial blood pressure during septic shock.

Why Is a Scalable Manufacturing Framework Vital for Future Pharmaceutical Security?

This collaboration is designed to be a scalable model that can be applied to other essential medicines identified by FDA and the WHO. The focus is on creating resilient supply assurance through tech-enabled processes and advanced development techniques. Eric Edwards, MD, PhD, CEO of Phlow, noted in a press release that, “Phlow is pioneering bold solutions to restore pharmaceutical sovereignty and strengthen America’s national health security”. He further commented, “For several years, we have worked alongside Fresenius Kabi to build resilient, end-to-end supply assurance for essential medicines. This expanded collaboration is focused on securing a reliable domestic supply of epinephrine, one of the most critical, life-saving drugs used across emergency and acute care settings in the United States.”¹ Pending necessary regulatory approvals, the product resulting from this domestic pipeline is expected to be available to US hospitals in 2027, potentially setting a new standard for how critical care medicines are developed and manufactured domestically.

How Else Is Fresenius Kabi Utilizing Collaborations?

Beyond the onshoring of traditional injectables, the drive for manufacturing innovation extends into the emerging field of cell and gene therapy. A strategic development agreement between Fresenius Kabi and TQ Therapeutics aims to enhance accessibility by enabling scalable and efficient manufacturing through integrated cell selection technology. Under this agreement Fresenius Kabi has the ability to develop, produce, and distribute products that are created with TQ Therapeutics’ proprietary cell selection technology.²

How Is Automated Cell Selection Streamlining Complex Manufacturing Workflows?

The integration of affinity and column-based isolation technology into automated processing systems is designed to produce high-purity cells quickly and consistently. This addresses the significant manufacturing challenges associated with process development and full commercialization. Saurabh Bhasin, head of Portfolio, Cell Therapies & contract manufacturing operations at Fresenius Kabi, noted in a press release,² “By integrating TQ Therapeutics’ novel selection technology into our Cue system, our aim is to improve manufacturing success and scalability—key steps toward supporting the advancement of cell and gene therapies.”

What Role Does Point-of-Care Processing Play in the Future of Individualized Medicine?

Advancing these technologies allows for ultra-short processes that can be performed closer to the point of care, simplifying treatment workflows. This modular approach supports the development of next-generation therapies delivered directly to the patient. “With Fresenius Kabi’s expertise in cell and gene therapy device technologies development and commercialization, and TQ Therapeutics’ focus on developing ultra-short processes for clinical cell therapies from manufacturing to in vivo applications, we are creating a novel value proposition for scaling and enabling the supply of cell therapies for broader patient populations,” stated Christian Eckert, CEO of TQ Therapeutics, in a press release. Such advancements reflect a broader commitment to utilizing technological knowledge to ensure access to world-class therapies through improved clinical practice and industrial production.

References

1. Fresenius Kabi. Fresenius Kabi and Phlow Corp. Announce First-Ever, End-to-End, U.S. Manufacturing Collaboration for Epinephrine Injection, USP. Press Release. Feb 9, 2026.
2. Fresenius Kabi. Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement. Press Release. Feb 9, 2026.

Source link

PharmaEssentia Plans New U.S. Manufacturing Facility In Puerto Rico

(Photo: PharmaEssentia)

Taiwan-based PharmaEssentia Corporation and its Massachusetts-based U.S. subsidiary PharmaEssentia USA Corporation will invest approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico. PharmaEssentia is a global biopharmaceutical company that develops novel biologics for hematology and oncology.

Ko-Chung Lin, Ph.D.
Founder, CEO / US General Manager, PharmaEssentia

The Puerto Rico operation will support the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing center for the U.S. market and long-term global demand for BESREMi®, a treatment for adults with polycythemia vera (PV). The project reflects sustained global demand growth for the biologic, particularly in the U.S., as well as the potential additional demand growth from regulatory approvals for new uses.

Puerto Rico is widely recognized as a leading global hub for pharmaceutical manufacturing, hosting a strong ecosystem of experienced talent, infrastructure, and regulatory expertise. The planned manufacturing facility is expected to provide several long-term strategic benefits for PharmaEssentia, including enhanced supply security, increased operational flexibility, improved cost efficiency, and scalable manufacturing capacity to support future growth.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia as we continue to strengthen supply resilience, scalability, and geographic diversification,” said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia. “We are proud to take this important step toward establishing U.S.-based manufacturing, with Puerto Rico serving as a future center for the U.S. market. This investment underscores our long-term commitment to reliably serving patients worldwide as demand for BESREMi® continues to grow.”

“PharmaEssentia’s decision to establish a manufacturing operation in Puerto Rico underscores the island’s role as a strategic U.S. hub for life sciences and advanced manufacturing,” said Governor of Puerto Rico Jennifer González. “This investment strengthens supply-chain resilience, creates high-value jobs, and reinforces Puerto Rico’s position as a trusted location for biopharmaceutical innovation and production serving patients in the United States and around the world.”

Read more about corporate expansion in the pharmaceuticals industry on Business Facilities.

Source link

Bulten Consolidates Manufacturing in the USA Following Review

Bulten AB, formerly FinnvedenBulten AB, is a Sweden-based company engaged in the provision of products, technical solutions and systems in metallic materials, primarily to the automotive industry. On June 30, 2014, the Company completed the divestment of its Finnveden Metal Structures (FMS) division to Shiloh Industries Inc. Its other business area, Bulten, offers fasteners to the European automotive market. It develops, manufactures and markets a range of metallic fasteners and related services. Its production processes include stamping, die casting and joining.

Source link

Manufacturing plant headed to Upper Macungie – Lehigh Valley Press

Eli Lilly and Company and the Lehigh Valley are joining together to build a new state-of-the-art manufacturing facility that will be designed for the research and production of injectable weight loss medications.

On Jan. 30 at Curiosity Hall in the Da Vinci Science Center, Allentown, an assortment of community members, business and political stakeholders joined Eli Lilly Chair and Chief Executive Officer Dave Ricks and Pennsylvania Gov. Josh Shapiro to announce a major collaboration.

Ricks said it is expanding manufacturing sites in the United States and considered 800 applicants for this project before choosing the Lehigh Valley. He credits the tenacity of Shapiro as this project will come to fruition at a site in Upper Macungie.

“Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we’re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines. We’re creating high‑quality jobs and collaborating across the region – with suppliers, educators and workforce development partners – to make critical medicines in the U.S.,” Ricks said. “That’s our commitment – to patients, to our new Pennsylvania home and to our country.”

The property in Upper Macungie Township, owned by the Jaindl Corporation (under contract to buy), will be the “single largest investment in economic development since the days of Bethlehem Steel,” Don Cunningham, Lehigh Valley Economic Development Corporation president and CEO said.

Manufacturing in Pennsylvania is 4% higher than the national average and is the largest industry within the state. Lilly proposes to invest $3.5 billion in this specific project. This will boost the Lehigh Valley economy on many levels.

For every dollar Lilly invests, it estimates up to $4 in additional local economic activity.

Ricks said Lilly is committed to the community and an interactive workforce development by including existing businesses and educational opportunities in its program. Lilly will connect with local nonprofits and encourage volunteerism.

Lehigh County Executive Josh Siegel pointed out, “Things are still made in the Valley and we should be proud of that. This is more than creating jobs and buildings; it is creating futures and careers for our residents and their families.”

This project will employ 850 engineers, scientists, operations personnel and lab technicians.

Lehigh Valley Building and Construction Trades Council President Paul Anthony pointed out the many benefits of the shared commitment to building a safe, quality facility by skilled union tradesmen. “Government, businesses and labor, working together has made this project happen,” Anthony said.

This project will offer employment in the building trades, as well as apprenticeships leading to skilled union jobs. Construction is expected to begin this year and Lilly expects to create 2,000 construction jobs. The site will be operational in 2031.

Shapiro also pointed out the permitting reforms, the Pennsylvania Economic Development for a Growing Economy (PA EDGE), a collection of tax credit programs designed to attract new investments from businesses in critical manufacturing sectors, as well as The Pennsylvania Strategic Investments to Enhance Sites Program (PA SITES), established to provide grant and loan funding to eligible applicants, helped this project.

PA SITES invested an initial $500,000.

The PA SITES program encourages businesses to build or relocate within Pennsylvania. The funding for the program includes two components that support the development of competitive sites within the commonwealth, and expansion of existing sites. Funding is made available through planning grants, construction grants and loans.

Ricks said this project is where “Curiosity meets Capability.” He reminded the audience of Lilly’s long history with pharmaceuticals starting post-Civil War. The emphasis was on defining ingredients and making safe, quality, accessible and affordable drugs for all Americans.”

The Lilly name will be seen throughout the valley.

“If it bares the red Lilly, you know it’s right,” Ricks said.

PRESS PHOTOS BY JENN RAGOEli Lilly and Company and the Lehigh Valley are joining together to build a new state-of-the-art manufacturing facility where 850 new pharmaceutical jobs and 2,000 union construction jobs will be available in the Lehigh Valley with the proposed manufacturing plant in Upper Macungie Township.

Pennsylvania Gov. Josh Shapiro announces a partnership with Eli Lilly and Company to build a manufacturing plant at a media event at the Da Vinci Science Center in Allentown.

Chair and Chief Executive Officer of Eli Lilly and Company Dave Ricks and Pennsylvania Gov. Josh Shapiro take questions after announcing the newest Lilly manufacturing plant to be built in Upper Macungie Township, Lehigh County.

Lehigh Valley Economic Development Corporation President and CEO Don Cunningham points out this was a bipartisan effort. Cunningham was instrumental in unifying all parties involved in this project.

Gov. Josh Shapiro speaks to a full house of guests at Curiosity Hall at the Da Vinci Science Center in Allentown. Shapiro announced the final plans to build a large manufacturing center in Upper Macungie.

“We still make things happen here [in the Valley. This project shows government delivering,” Lehigh County Executive Josh Siegel tells the crowd.

Eli Lilly and Company Chair and Chief Executive Officer Dave Ricks explains the growth of the life science industry as Gov. Josh Shapiro mentions this facility will include research as well as manufacturing.

Gov. Josh Shapiro and Chair and Eli Lilly and Company Chief Executive Officer Dave Ricks place the Lilly pin/marker on the map of the Lehigh Valley, denoting where Lilly will make their mark.

Eli Lilly and Company Chair and Chief Executive Officer Dave Ricks tells the audience “800 municipalities and sites were considered for this project.” Upper Macungie Township was chosen for Lilly’s injectable manufacturing plant.

Source link

Siemens Energy to Invest $1 Billion in U.S. Manufacturing, Add 1,500 Jobs

Siemens Energy plans to invest $1 billion to expand U.S. manufacturing capacity for grid equipment and gas turbines, adding more than 1,500 jobs as power demand accelerates from data centers, AI infrastructure and electrification.

(P&GJ) — Siemens Energy has finalized plans to invest $1 billion to expand manufacturing operations across the United States, a move that will create more than 1,500 highly skilled jobs as electricity demand rises sharply due to data centers, artificial intelligence infrastructure and industrial electrification.

The investment builds on plans outlined at the company’s Capital Market Day in Charlotte, North Carolina, last November and includes a mix of brownfield expansions and one greenfield project. Siemens Energy said the program will increase domestic production of grid equipment, transformers and large gas turbines, while strengthening U.S.-based manufacturing capacity to meet growing demand.

As part of the expansion, Siemens Energy will construct a new high-voltage switchgear manufacturing facility in Mississippi and expand transformer production, gas turbine manufacturing and grid technology operations in several states. The company said the approach allows it to use manufacturing capacity efficiently while supporting long-term market growth.

“Siemens Energy has been making things in the United States for more than a century and we are experiencing a once-in-a-generation growth opportunity due to the resurgence of U.S. manufacturing and the growth of artificial intelligence,” said Christian Bruch, CEO and President of Siemens Energy. “The current policy environment has contributed to this momentum. The Trump Administration has made energy security, a reliable and resilient grid, and growing U.S. manufacturing jobs a priority. This has supercharged the energy demand which is supporting new investments across the energy sector. We are excited to help write this next chapter of American energy expansion.”

The expansion is expected to add more than 1,500 roles across manufacturing, engineering and operations. Siemens Energy said it will also expand apprenticeship programs and training initiatives to support workforce development across the energy industry.

“This tremendous investment in a critical part of our power grid supply chain underscores President Trump’s success in expanding supply chain access and bringing major manufacturing back to America,” said U.S. Interior Secretary Doug Burgum. “We appreciate great partners like Siemens Energy, who proactively partner with the Trump administration for the benefit of the American people, prioritizing critical components to make the United States Energy Dominant!”

Planned Site Investments

Siemens Energy said the investment will be spread across multiple states:

• Mississippi (Greater Richland area): Construction of a new high-voltage switchgear plant, including a training center, with plans to hire up to 300 employees.

• North Carolina (Charlotte, Winston-Salem and Raleigh): Expanded transformer manufacturing and servicing, resumption of gas turbine manufacturing in Charlotte, turbine component production in Winston-Salem, and expanded grid technology, engineering and R&D operations in Raleigh. About 500 jobs are expected across the state.

• Florida (Orlando and Tampa): Expansion of turbine blade and vane manufacturing in Tampa and upgrades to research and development capabilities in Orlando, including an artificial intelligence digital grid technologies laboratory with NVIDIA. The company will also relocate and modernize its regional headquarters in Orlando.

• Alabama (Fort Payne): Expanded production of copper and insulation components for generators, creating about 120 jobs.

• New York (Painted Post) and Texas (Houston): Facility upgrades supporting the manufacture and servicing of compression equipment used to transport gas and liquids through pipelines.

Siemens Energy said the U.S. remains a core market for the company, accounting for nearly 29% of global order volume last fiscal year. The company currently employs more than 12,000 people across 25 U.S. facilities and works with nearly 5,000 domestic suppliers.

Source link

US manufacturing access opens new Alpha-GPC format options as cognitive health market matures

According to market insights firms SPINS, U.S. cognitive health vitamin, mineral and supplement sales reached approximately $499 million over the latest 52-week period, with unit sales exceeding 19.5 million. While the category remains one of the industry’s largest condition-specific segments, dollar sales declined slightly year over year, underscoring the difficulty of sustaining growth in a mature market.

Within that landscape, CHEMI Nutra says expanded U.S. manufacturing access to its choline-rich Alpha-GPC ingredients is enabling shorter formulation timelines while preserving Italian pharma-level purity and stability. CHEMI Nutra, incorporated in 2001, manufacturers Alphasize at CHEMI S.p.A.’s pharmaceutical-grade facilities in Milan and Patrica, Italy.

Alpha-GPC (Alpha-glycerylphosphorylcholine) is used across a wide range of cognitive health products, particularly in blended formulations positioned for focus, memory and mental performance. Its use, however, has largely remained concentrated in powders and capsules.

Accessing the AlphaSizeLiquid-Science Platform

Mike Petteruti, president & general manager of CHEMI Nutra highlighted that delivery format innovation continues to shape future development strategies for choline ingredients.

“Future development will focus on delivery systems that improve bioavailability, format flexibility and consumer compliance, including liquids, softgels and hybrid systems,” he told NutraIngredients. “The biggest opportunity lies in integrating choline solutions into multi-benefit formulations without compromising stability or sensory experience.”

Efforts to expand Alpha-GPC into liquid and softgel formats have historically faced stability challenges, and the “main barriers were limited access to suitable liquid Alpha-GPC and a lack of confidence and know-how around softgel applications,” according to Petteruti.

“Alpha-GPC’s sensitivity to moisture and interaction with lipid systems made long-term stability difficult without system-level expertise,” he noted.

Those issues have limited how quickly brands could pursue alternative delivery formats, but Petteruti said those challenges can now be addressed via CHEMI Nutra’s AlphaSize Liquid-Science Platform.

Introduced in 2025, this platform allows for the use of “Liquid 85L” Alpha-GPC in applications such as shots, ready-to-drink (RTD) beverages, gummies, drops and softgels, while maintaining the stability and efficacy of the ingredient.

Moving forward, Petteruti added, regulatory clarity and scientific substantiation will continue to influence how quickly new formats reach the market.

Added value of U.S. manufacturing and regulatory clarity

As competition heats up, regulatory positioning is also playing a more substantial role in ingredient selection. Alphasize is the only New Dietary Ingredient (NDI)-cleared Alpha-GPC in the U.S. market.

“Expanded U.S. manufacturing access to an NDI-supported Alpha-GPC increases regulatory confidence and commercial clarity for brands,” Petteruti said. “NDI support provides a well-documented safety and quality foundation, while domestic production improves traceability, continuity and alignment with FDA expectations.”

He added that those factors shorten supply chains and allow brands to plan innovation cycles with greater certainty in cognitive health and brain-mood formulations.

US-based manufacturing is also becoming more closely tied to transparency and documentation expectations.

“The AlphaSize Liquid-Science platform combines U.S.-based manufacturing with the same transparency and quality standards applied across CHEMI Nutra’s global operations,” Petteruti said. “Domestic production enables clearer documentation, tighter quality oversight and closer collaboration around formulation, stability and delivery formats.”

On-shoring can also make technical or regulatory decision-making processes less complex, as it “provides more direct access to this know-how and more consistent answers around regulatory confidence and performance expectations,” he added.

Source link